| abstract |
The invention discloses an anti-SARS-CoV-2 fully humanized monoclonal antibody and its application. The antibody 6G2 was screened by flow sorting-single-cell PCR technology, has a unique CDR partition, and can bind to the RBD region of the Spike glycoprotein of SARS-CoV-2, blocking the binding of the Spike protein to the host membrane protein ACE2 , thereby neutralizing the novel coronavirus. The monoclonal antibody 6G2 disclosed in the present invention not only has efficient and specific neutralizing activity against SARS-COV-2, but also has the characteristics of high expression, fully human origin and good stability, and is suitable for industrial production. The antibodies disclosed in the present invention have broad application prospects, for example, they can be used to prepare novel coronavirus detection products, or to prepare medicines for preventing and treating novel coronavirus diseases, and have important biological and medical significance. |